Document:

Exhibit 10.6

 

REVOLVING LOAN AGREEMENT

 

THIS
REVOLVING LOAN AGREEMENT (this “Agreement”) is made as of October 14, 2020 (the “Effective Date”),
by and between Medigus Ltd. an entity organized and existing under the laws of Israel (“Creditor”), and
Eventer Technologies Ltd., an entity organized and existing under the laws of Israel (“Debtor”).

 

		1.	THE LOAN.

 

		1.1	THE ADVANCES.

 

		(a)	COMMITMENT. From time to time, subject to the conditions in subparagraph
1.1(b) and 1.1(d) hereof, Creditor agrees to lend to Debtor hereunder, in one or more borrowings (an “Advance”
or “Advances”), such sums not to exceed at any one time outstanding One Million
and Two Hundred and Fifty Thousand USD ($1,250,000.00) (“Commitment”). Subject
to the provisions of this Agreement, each Advance may be repaid and reborrowed in part or in full at any time and from time to
time hereunder. Creditor may, in its sole discretion, decline to make any Advance only if there is been, or with the passage of
time or notice, or both, there would be, an Event of Default (as defined in Section 4 hereof) which is then continuing.

 

		(b)	NOTICE PERIOD. The disbursement of each Advance shall be made
upon written notice received by Creditor (in the form or information similar to the attached as Exhibit 1) (each, an “Advance
Notice”), not later than seven Business Days prior to the date of an Advance specifying
the date of disbursement (which date shall be a Business Day) and the amount of the Advance. The Creditor may decide, in its sole
discretion, if to make the Advance in USD or NIS. “Business Day” means any
day other than a Saturday or other day on which pertinent commercial banks are authorized or required by law to close in Israel.
Notwithstanding the foregoing, on the Effective Date, and without the Advance Notice Requirement (but subject to subparagraph 1.1(d)),
the Creditor shall disburse to the Debtor an amount equal to Two Hundred and Fifty Thousand USD ($250,000) (the “Initial
Advance”).

 

		(c)	NOTICE CONFIRMATION. Notwithstanding anything to the contrary
in this Agreement, all notices to be given by Debtor hereunder shall be in writing pursuant to Section 4.1 hereof or by telephone.
Each telephonic notice shall be confirmed immediately in writing by Debtor. If there is any discrepancy between the telephonic
notice accepted by Creditor and the written confirmation, the terms of the written notice shall be conclusive and binding.

 

		(d)	PURPOSE. The Debtor will use the Initial Advances for research
and development, growth and expansion purposes, and all other Advances for ongoing operations and activities, as also detailed
a plan approved by the Creditor, upon signing of this Agreement (the “Business Plan”).
Creditor’s approval shall be required for each Advance. Such Business Plan may be amended and updated from time to time by
the Board of Directors of the Debtor (including the Medgius Directors (as defined in the Company’s Amended and Restated Articles
of Association).

 

     

     

    

 

		1.2	MATURITY. The repayment of each
Advance shall be as follows: (a) with respect to each Advance (except for the Initial Advance), immediately (and in no event more
than 30 days) following the completion of the project for which purpose the Advance was made (it being clarified that if the Advance
was made in connection with a certain performance or event, then the date of such performance or event shall be deemed the completion
date), and (b) with respect to the Initial, commencing on the 1st anniversary of the payment date of such Advance, the
Creditor shall repay the applicable Advance (and all accrued interest) in twenty four (24) equal monthly installments. The date
by which all repayments with respect to a certain Advance shall be made, shall be referred to as the “Maturity Date”.

 

		1.3	INTEREST ON ADVANCES. Outstanding
principal balances on the Advances shall bear interest at a rate equal to the higher
of: (i) of 4% (for percent) per annum, or (ii) the interest rate determined by the Israeli Income
Tax Ordinance [New Version] 5721-1961, and the rules and regulations promulgated thereunder. Interest shall accrue on each Advance
from the date such Advance is made until such Advance and all accrued and unpaid interest relating to such Advance is repaid. Interest
shall be calculated on the basis of a 360-day year for the actual number of days elapsed.

 

		1.4	PAYMENT OF INTEREST. Interest
shall be payable monthly in accordance with the above Section 1.2. All payments with respect to the Advances received on the interest
due date shall be applied first to the payment of interest and all charges or expenses payable by Debtor to Creditor hereunder
(in such order as Creditor may determine) and the balance, if any, to principal. All full or partial repayments of Advances, not
including the interest payments referred to in this Section 1.4, shall be governed by the terms of Section 1.6 hereof. Taxes shall
be withheld from any payment of interest under this Agreement to the extent required under any applicable law (including any applicable
tax treaty) and in such case interest payment shall be reduced by such taxes. 

 

		1.5	DEFAULT INTEREST. During the
continuation of an Event of Default, upon notice by the Creditor to the Debtor, the interest rate shall be 2% per annum plus the
rate set forth in Section 1.3 hereof.

 

		1.6	VOLUNTARY REPAYMENT. Debtor
may repay any Advance from time to time, without premium or penalty. Creditor in its sole discretion shall determine how and in
what proportions to apply amounts prepaid against the principal and/or accrued interest of each Advance. 

 

		1.7	FORM OF PAYMENT. All payments
of principal and interest payable to Creditor shall be made in the currency of the Commitment (as set forth in Section 1.1.1 hereof)
in immediately available funds, without setoff or counterclaim. 

 

		1.8	LEGALITY. Creditor shall not
be required to make any Advance unless the making of such Advance shall not subject Creditor to any penalty or special tax, shall
not be prohibited by any law or governmental order or regulation applicable to Creditor or to Debtor or its subsidiaries, and all
necessary consents, approvals and authorizations of any person for any such Advance shall have been obtained. Creditor and Debtor
agree to use reasonable efforts to obtain such consents, approvals and authorizations, if available.

 

    2

     

    

 

		2.	FUNDING AND TERMINATION.

 

		2.1	CLOSING DELIVERABLES. Upon signing of this Agreement the
following shall have been met:

 

		(a)	EXECUTED COUNTERPARTS. The parties hereto shall have exchanged
executed counterparts of this Agreement.

 

		(b)	CORPORATE AUTHORIZATION. The execution, delivery and performance
by the parties of this Agreement have been duly authorized by all required corporate or other action.

 

		(c)	BUSINESS PLAN. The receipt of a Business Plan satisfactory to
the Creditor.

 

		2.2	TERMINATION.

 

This
Agreement shall terminate on the third anniversary of the Effective Date; provided, however, that any Advances then
outstanding shall remain outstanding and subject to the provisions of this Agreement until the end of their respective Maturity
Dates. Notwithstanding the aforesaid, this Agreement may continue in full force and effect either at the sole discretion of Creditor,
or if requested by Debtor, with consent by Creditor. 

 

		3.	NO RIGHT OF SET-OFF. Except as otherwise agreed between Creditor
and Debtor, Creditor is not authorized to and shall not set off or apply any amounts at any time held by Creditor and owing to
Debtor, or any other indebtedness at any time owing by Creditor to Debtor, against any Advance or any of Debtor's other obligations
hereunder.

 

		4.	EVENTS OF DEFAULT. The occurrence of any of the following events
(“Events of Default”) shall terminate any obligation on the part of Creditor
to make any Advance or to continue any Advance and, at the option of Creditor, shall make all sums of interest and principal remaining
on any Advance immediately due and payable, without notice of default, presentment or demand for payment, protest or notice of
nonpayment or dishonor, or other notices or demands of any kind or character.

 

		4.1	OVERDUE PRINCIPAL. Debtor shall
fail to pay any principal amount of any Advance when due in accordance with the terms hereof and not rectify such failure within
30 days from Creditor's written demand.

 

		4.2	OVERDUE INSTALLMENTS OF INTEREST. Debtor
shall fail to pay within 10 Business Days when due any installment of interest in accordance with the terms hereof, and not rectify
such failure within 30 days from Creditor's written demand.

 

		4.3	INSOLVENCY. (a) Debtor becomes
insolvent or generally fails to pay, or admits in writing its inability to pay, its debts as they become due or files a petition
to take advantage of any applicable bankruptcy, insolvency or reorganization statute or similar law of any jurisdiction now or
hereafter in effect; (b) Debtor makes a general assignment for the benefit of creditors or applies for or consents to the appointment
of a trustee, interim trustee, custodian, administrator, conservator, receiver or liquidator in any bankruptcy, reorganization,
arrangement, insolvency, readjustment of debt, marshalling of assets and liabilities or similar proceedings of or relating to Debtor,
as the case may be, or of or relating to a substantial portion of the property of, Debtor or for the winding up, dissolution or
liquidation of Debtor; (c) such a receiver, trustee, interim trustee, custodian, administrator, conservator, receiver or liquidator
otherwise shall be appointed and shall not be discharged within 45 days after such appointment; or (d) if any order for relief
under any applicable bankruptcy law shall be entered in any proceeding by or against Debtor.

 

		4.4	DILUTION OF CREDITOR'S HOLDINGS. Creditor
ceases to hold over 25% of the voting rights of the Debtor.

 

    3

     

    

 

		5.	CREDITOR RIGHTS. Upon the occurrence of an Event of Default,
Creditor may avail itself of any legal or equitable rights that Creditor may have at law or in equity or under this Agreement.
The remedies of Creditor as provided herein shall be distinct and cumulative, and may be pursued singly, successively or together,
at the sole discretion of Creditor, and may be exercised as often as occasion therefor shall arise. Failure to exercise any of
the foregoing options upon the occurrence of an Event of Default shall not constitute a waiver of the right to exercise the same
or any other option at any subsequent time in respect to the same or any other Event of Default, and no single or partial exercise
of any right or remedy shall preclude other or further exercise of the same or any other right or remedy.

 

		6.	SECURITY. This Agreement is secured by a Floating Charge
Agreement (as amended from time to time, the “Floating Charge Agreement”)
between Creditor and Debtor, of even date herewith.

 

		7.	DEFAULT PAYMENT. With respect to each Advance, the Debtor
may, at its sole discretion, on the Maturity Date of such Advance, convert any unpaid portion of the Advance to Ordinary Shares
of the Company, calculated in accordance with the formula set forth in Section 7.2(e) of that Share Purchase Agreement by and between
the Creditor and the Debtor dated as of an even-date.

 

		8.	MISCELLANEOUS

 

		8.1	CONFIDENTIALITY. Save as required
for under applicable law, each Party hereby undertakes to the other Party to maintain the existence of this Agreement and its content
in confidence, and not disclose or convey its content or existence to any person and/or entity whatsoever, other than as is reasonably
required for the purpose of carrying out its obligations hereunder, without the prior written consent of the other Party.

 

		8.2	NOTICES. Any communications
between the parties hereto or notices provided herein to be given may be given by personal delivery or mailing the same, postage
prepaid, to Creditor at Omer Industrial Park, No. 7A, P.O Box 3030, Omer 8496500, Israel and to Debtor at Bezalel 4, Ramat Gan;
or to such other address as either party may in writing hereafter indicate. Notices shall be deemed effective on the date received.

 

		8.3	INFORMATION RIGHTS.

 

		(a)	Initial Documentation. Debtor has provided to Creditor written
documentation and information regarding Debtor's financial position, specifically including all information pursuant to that certain
Share Purchase Agreement dated as of October 14, 2020, entered into by and between Debtor and Creditor, and Creditor is aware of
and familiar with Debtor's current state of affairs and financial position.

 

		(b)	Ongoing Rights. Creditor may from time to time reasonably request
information regarding the business, financial or corporate affairs of Debtor. In the event of such a request, Debtor shall deliver
to Creditor promptly any such information requested.

 

		8.4	ASSIGNMENT. This Agreement shall
bind and inure to the benefit of the parties hereto and their respective successors and assigns. Creditor may assign its rights
under this Agreement (but not its obligations) without the consent of Debtor. Debtor shall not assign this Agreement or any of
the rights, duties or obligations of Debtor hereunder without the prior written consent of Creditor.

 

    4

     

    

 

		8.5	WAIVERS. No delay or omission to exercise any right, power
or remedy accruing to Creditor upon any breach or default of Debtor under this Agreement shall impair any such right, power or
remedy of Creditor, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or
in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring.

 

		8.6	SEVERABILITY. The illegality or unenforceability of any
provision of this Agreement shall not in any way affect or impair the legality or enforceability of the remaining provisions of
this Agreement. 

 

		8.7	GOVERNING LAW. This Agreement shall be governed by and construed
in accordance with the laws of the State of Israel, disregarding its conflict of laws rules.

 

		8.8	SEPARATE COUNTERPART; AMENDMENTS. This
Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. This Agreement may be amended only by an instrument in writing duly signed by
all parties hereto.

 

		8.9	ENTIRE AGREEMENT. This agreement
supersedes any previous agreement between the parties in relation to the matters dealt with herein and represents the entire understanding
between the parties with respect to such matters.

 

[The remainder of
this page is intentionally left blank]

 

    5

     

    

 

IN
WITNESS WHEREOF, the parties have duly executed this Agreement effective as of the Effective Date.

 

	 	MEDIGUS
    LTD.
	 	 
	 	By:	 /s/ Eli Yoresh
	 	Name:  	 Eli Yoresh
	 	Title: 	Chairman
	 	 
	 	By: 	/s/ Liron Carmel
	 	Name: 	Liron Carmel
	 	Title: 	Chief Executive Officer
	 	 
	 	EVENTER
    TECHNOLOGIES LTD.
	 	 
	 	By: 	/s/ Eli Uzan
	 	Name:	 Eli Uzan
	 	Title: 	Chairman
	 	 
	 	By: 	/s/ Julien Azoulay 
	 	Name: 	Julien Azoulay
	 	Title: 	Chief Executive Officer

 

    6

     

    

 

Exhibit
1

 

NOTICE
OF ADVANCE

 

Under
the terms of the Revolving Loan Agreement effective as of [ ] , Debtor hereby requests the following Advance:

 

Sum
requested: ___________

 

Date
of request: __________

 

Sums
previously advanced and outstanding : __________

 

Accrued
interest to date of request: _____________

 

Total
loan facility utilized after this request: ___________

 

Debtor
hereby confirms that none of the events specified in section 4 of the Revolving Loan Agreement (“Events Of Default”)
have occurred.

 

	 	EVENTOR
    TECHNOLOGIES LTD.
	 	 
	 	By:	 
	 	Name:  	                    
	 	Title:	 

 

 

7Exhibit
10.7

 

SHARE
EXCHANGE AGREEMENT

 

THIS
SHARE EXCHANGE AGREEMENT (this “Agreement”) is made as of October 14, 2020 (the “Effective Date”),
by and among Medigus Ltd. an entity organized and existing under the laws of Israel (“Medigus”) the
shareholders of Eventer Technologies Ltd., an entity organized and existing under the laws of Israel (the “Company”),
listed on Exhibit A hereto (each, a “Shareholder” and collectively, the “Shareholders”),
and Eli Uzan solely in its capacity as the representative of the Shareholders (the “Representative”).

 

RECITALS

 

WHEREAS,
Medigus has entered into that certain Share Purchase Agreement by and between Medigus and the Company, pursuant to which Medigus
acquired Ordinary Shares (the “SPA”) (terms not defined herein shall have the meaning given to them in the
SPA);

 

WHEREAS,
Medigus, the Company and the Shareholders agreed that, during the Exercise Period, each Shareholder shall have an option to transfer
the Eventer Shares held by such Shareholder to Medigus in exchange for the issuance by Medigus of Medigus Shares, all in accordance
with the terms herein (the “Share Exchange”);

 

NOW,
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

	1.	DEFINITIONS.

 

		1.1	“Exchange
                                         Date” means that date on which the Eventer Shares
                                         are exchanged for the benefit of the Medigus Shares

 

		1.2	“Exercise
                                         Period” means the period commencing on the 2nd
                                         anniversary of the Effective Date and ending on the date that is 54 months following
                                         the Effective Date (i.e. 4 and a half years).

 

		1.3	“Eventer
                                         FMV” means the fair market value of one Eventer
                                         Share at the time of Share Exchange, as shall be mutually determined by Medigus and the
                                         Shareholder exercising the Option; provided, however, that if Medigus and the Shareholder
                                         cannot agree on the fair market value of the Eventer Share, the fair market value shall
                                         be determined by calculating the average ratio of the market cap to EBIDTA (as published
                                         on the then most-recent annual audited financial statements) of two public companies
                                         in the industry of the Company (which, unless otherwise mutually agreed by Medigus and
                                         the Representative, shall be Live Nation Worldwide, Inc. and CTS Eventim AG) and multiplying
                                         such ration by the Company’s EBIDTA (as published on the then most-recent annual
                                         audited financial statements of the Company). 

 

		1.4	“Eventer
                                         Share Value” means the product obtained from
                                         multiplying
                                         the number of Eventer Shares held by a certain Shareholder
                                         by the Eventer FMV.

 

		1.5	“Eventer
                                         Shares” means the Ordinary Shares of the Company,
                                         par value NIS 0.10, as may be adjusted from time to time following splits, issuance of
                                         bonus shares, etc.

 

		1.6	“ITA”
                                         means the Israeli Tax Authority.

 

		1.7	“ITO”
                                         means the Israeli Tax Ordinance (New Version), 1961, as amended, and all rules and regulations
                                         promulgated thereunder.

 

		1.8	“Medigus
                                         Share Price” means the average closing price
                                         of one Medigus Share on the Tel Aviv Stock Exchange Ltd. (“TASE”)
                                         (or if Medigus Shares are not traded on TASE, on the principal market where such shares
                                         or ADSs representing such shares are traded) for a period of 60 consecutive trading days
                                         ending on (and including) the third trading day immediately prior to the Exchange Date.

 

     

     

    

 

		1.9	“Medigus
                                         Shares” means Ordinary Shares of Medigus, NIS
                                         1.00 par value.

 

		1.10	“Revolving
                                         Loan Agreement” means that certain Revolving
                                         Loan Agreement by and between Medigus and the Company dated as of an even-date hereof.

 

		1.11	“Securities
                                         Act” means the U.S. Securities Act of 1933, as
                                         amended.

 

		1.12	“Valid
                                         Certificate” means a certificate, ruling, approval
                                         or any other written instructions issued by the ITA applicable to the Medgius Shares
                                         to be received by the applicable Shareholder indicating that no withholding (or reduced
                                         withholding or any other instructions regarding withholding) of Israeli tax is required
                                         with respect to the holder of such certificate, ruling or approval in form and substance
                                         satisfactory to Medgius.

 

	2.	THE
                                         EXCHANGE.

 

		2.1	THE
                                         OPTION. During the Exercise Period, and subject to
                                         Section ‎2.2, Section 2.3 and Section 3, the Representative, on behalf of all Shareholders,
                                         shall have an option to exchange all (but not less than all) of the Ordinary Shares held
                                         by the Shareholders in exchange for such number of Medigus Shares (the “Option”).
                                         The number of Medigus Shares into which a Shareholder’s Ordinary Shares shall be
                                         converted shall be determined by dividing:
                                         (a) such Shareholder’s Eventer Share Value, by (b)
                                         the Medigus Share Price, and rounding the resulting number down to the nearest whole
                                         number of shares of Medigus Shares. 

 

		2.2	LIMITATIONS.
                                         Notwithstanding Section 2.1, Medigus shall not be obligated
                                         to effect the Share Exchange on the Record Date (as such term is defined under the TASE
                                         rules and regulations) of: (i) a distribution of bonus shares; (ii) a rights offer; (iii)
                                         any distribution of dividends; (iv) a consolidation of the share capital of Medigus;
                                         (v) a share split; or (vi) a reduction of the share capital of Medigus (each of the aforementioned
                                         events shall be called: “Corporate Event”).
                                         In addition, if the Ex-Date (as such term is defined under the TASE rules and regulations)
                                         of a Corporate Event occurs before the Record Date of a Corporate Event, then the Option
                                         shall not be exercised on the Ex-Date. Medigus shall also not be required to effect the
                                         Share Exchange if Medigus’ Board of Directors determines, in its good faith judgement,
                                         that it would be materially detrimental to the Company and its shareholders to effect
                                         the Share Exchange on the requested date, then Medigus shall have the right to defer
                                         taking action for a period of not more than sixty (60) days after the request to effect
                                         the Share Exchange. Any delay to the Share Exchange caused as a result of this Section
                                         2.2 shall extend the Exercise Period by the amount of days in which the Share Exchange
                                         was delayed.

 

		2.3	NO
                                         EXCHANGE. Notwithstanding Section 2.1, the Shareholders
                                         shall not be entitled to effectuate the Share Exchange if: (i) the outstanding Advances
                                         (as defined in the Revolving Loan Agreement) are equal to, or greater than, US$ 600,000,
                                         unless approved by Medigus, at its discretion, or (ii) an Event of Default (as defined
                                         in the Revolving Loan Agreement) has occurred.

 

		2.4	SPECIAL
                                         RIGHTS. Notwithstanding Section 2.1, if at any time
                                         prior to the Exercise Period, Medigus exercises any of its rights under 6.3 in the Restated
                                         Articles of Association, while the Representative has not affirmatively approved Medigus’s
                                         action (the date such actions shall be taken will be deemed the “Decision
                                         Date”), then in such case the Representative
                                         may, within sixty days from the Decision Date, request that Medigus either (i) effect
                                         the Share Exchange under the terms of this Agreement, or (ii) purchase all of the Eventer
                                         Shares held by the Shareholders for an amount per share equal to the Eventer Share Value.
                                         Medigus may, in its sole discretion, determine, whether it wishes to effect the Share
                                         Exchange or purchase the Eventer Shares. 

 

    2

     

    

 

	3.	TAX
                                         MATTERS; WITHOLDING.

 

		3.1	Notwithstanding
                                         any other provision of this Agreement to the contrary, Medgius shall be entitled to deduct
                                         and withhold from any consideration actually payable or otherwise deliverable to any
                                         Seller hereunder, including such portions of the Medigus Shares, actually payable or
                                         otherwise deliverable to the Shareholders such amounts as Medigus may be required to
                                         deduct or withhold therefrom under the ITO, or any legal requirement with respect to
                                         tax which is applicable to the making of such payment. To the extent that such amounts
                                         are so withheld by the Medigus, (i) such withheld amounts shall be treated for all purposes
                                         as having been paid to the Shareholder to whom or to which such amounts would otherwise
                                         have been paid; and (ii) such withheld amounts shall be remitted by Medigus to the applicable
                                         governmental entity.

 

		3.2	Without
                                         limiting the generality of the foregoing, the parties hereto agree that, no withholding
                                         or a reduced amount of withholding under the ITO will be made from any consideration
                                         payable or otherwise deliverable hereunder to any Shareholder if such Shareholder provides
                                         Medgius with a Valid Certificate, at least five (5) business days prior to the time such
                                         payment of consideration is to be made. 

 

		3.3	For
                                         the avoidance of doubt, Medigus shall not be required to issue any Medigus Shares to
                                         any Shareholder, unless a Valid Certificate providing for a full exemption is delivered
                                         to Medigus by such Shareholder or that the applicable amounts required to be withheld
                                         are paid by such Shareholder. For the avoidance of doubt, Medigus shall have, in its
                                         sole discretion, the authority but not the obligation to withhold any taxes at the applicable
                                         rate, and consequently issue to each Shareholder its respective amount of Medgius Shares
                                         less such numbers of shares that represent the amount that was withheld at the source.

 

	4.	REPRESENTATIONS.

 

		4.1	Each
                                         Shareholder represents and warrants (severally and not jointly, with respect to itself
                                         only) to Medigus that the following representations and warranties are true and correct
                                         in all respects as of the date hereof and shall be true and correct in all respects as
                                         of the applicable Exchange Date:

 

		(a)	Authorization;
                                         Validity. Such Shareholder has the requisite power and authority to execute and deliver
                                         this Agreement and to perform its obligations hereunder. This Agreement has been duly
                                         executed and delivered and constitutes the lawful, valid and legally binding obligation
                                         of such Shareholder, enforceable in accordance with its terms and conditions except as
                                         may be limited by applicable bankruptcy, insolvency, reorganization, moratorium laws,
                                         and other laws of general application affecting the enforcement of creditors’ rights
                                         and remedies generally and general principles of equity.

 

    3

     

    

 

		(b)	Compliance
                                         with Other Instruments. The execution, delivery and performance of this Agreement
                                         and the consummation of the transactions contemplated hereby by such Shareholder will
                                         not result in any violation or default reasonably expected to render the transactions
                                         contemplated hereby null, void and of no force and effect under: (a) any instrument,
                                         judgment, order, writ or decree which binds such Shareholder; (b) any note, indenture
                                         or mortgage applicable to such Shareholder; (c) any agreement or other instrument to
                                         which such Shareholder is a party or by which it is bound; or (d) any provision of any
                                         law, rule or regulation applicable to such Shareholder. Neither the execution and delivery
                                         of this Agreement and any other agreements contemplated hereby or ancillary hereto, nor
                                         the compliance, by such Shareholder with the terms and provisions hereof or thereof,
                                         will result in the creation or imposition of any liens, claims, encumbrances or third
                                         party rights of any kind in respect of the Eventer Shares exchanged and transferred by
                                         such Shareholder pursuant hereto.

 

		(c)	Consents.
                                         Such Shareholder is not required to obtain any consent, approval, permit, declaration,
                                         registration, or authorization by, or filing with, any person, including any applicable
                                         court, governmental or regulatory authority, commission, administrative agency, or non-governmental
                                         third party, in connection with the execution and performance of this Agreement or the
                                         consummation of the transactions contemplated hereunder.

 

		(d)	The
                                         Eventer Shares. Such Shareholder is the sole owner of the Eventer Shares set forth
                                         opposite its name in the Capitalization Table, beneficially and of record. At the applicable
                                         Exchange Date, the Eventer Shares exchanged by such Shareholder at such Exchange Date
                                         will be free and clear of any pledge, lien, hypothecation, encumbrance, charge, claim,
                                         or other security interest of any kind, or any other right of any third party (“Security
                                         Interest”), and upon transfer thereof to the
                                         Shareholder, Medigus will have good and valid title to such Eventer Shares, beneficially
                                         and of record, free and clear of any Security Interest, with the rights attached thereto
                                         under the Restated Articles.

 

		(e)	Litigation.
                                         There is no action, suit, investigation or proceeding pending or, to such Shareholder’s
                                         knowledge, threatened against such Shareholder before any court, arbitrator or any governmental
                                         authority which, if determined or resolved in a manner adverse to such Shareholder, would
                                         reasonably be expected to challenge or seek to prevent, enjoin, alter or delay the transactions
                                         contemplated hereby.

 

		(f)	Exchange
                                         for Own Account. The Shareholder is exchanging its Eventer Shares for its own account.

 

		(g)	Sophisticated
                                         Shareholder. Such Shareholder acknowledges that following the applicable Exchange
                                         Date, such Shareholder will have no future participation in any Company gains, losses,
                                         profits or distributions with respect to the Eventer Shares exchanged by such Shareholder
                                         at such Exchange Date. If such Eventer Shares increase in value by any means, or if the
                                         Company’s equity becomes freely tradable and increases in value, such Shareholder
                                         acknowledges that it is voluntarily forfeiting any opportunity to share in any resulting
                                         increase in value from such Eventer Shares. Such Shareholder further acknowledges and
                                         represents that (a) it has not relied on any representation or statement of Medigus or
                                         the Company, nor of any of their respective officers, directors, employees or agents,
                                         regarding the present or future value of such Eventer Shares, or the advisability of
                                         the decision to exchange such Eventer Shares for the Medigus Shares, and (b) neither
                                         Medigus or the Company, nor any of their respective officers, directors, employees or
                                         agents, is acting as a fiduciary or financial or investment adviser to such Shareholder,
                                         or has given such Shareholder any investment advice, opinion or other information on
                                         whether the exchange of such Eventer Shares is prudent.

 

    4

     

    

 

Such
Shareholder further acknowledges that (i) Medigus currently may have, and/or later may come into possession of, information with
respect to the Company that is not known to such Shareholder and that may be material to a decision to exchange the Eventer Shares
at the applicable Exchange Date (“Shareholder
Excluded Information”), (ii) it has elected to exchange such Eventer Shares notwithstanding
its lack of knowledge of the Shareholder Excluded Information, and (iii) neither Medigus, the Company nor any of their officers,
directors, employees, or agents shall have liability to such Shareholder, and such Shareholder waives and releases, any claims
that it might have against any of the foregoing, whether under applicable securities laws or otherwise, with respect to the nondisclosure
of the Shareholder Excluded Information.

 

		(h)	Tax
                                         Matters. Such Shareholder has had an opportunity to review with its tax advisers
                                         the federal, state, local, and/or foreign tax consequences of the transactions contemplated
                                         hereby, and such Shareholder is relying solely on such advisers and not on any statements
                                         or representations of Medigus, the Company, or any of their respective agents. Such Shareholder
                                         understands and acknowledges that the Shareholder (and not Medigus) shall be responsible
                                         for, and shall solely bear, all of the Shareholder’s tax liability (including withheld
                                         tax liabilities) and any and all related interest and penalties that may arise, or imposed
                                         by any taxing authority, domestic or foreign, as a result of or in connection with the
                                         transactions contemplated hereby.

 

		(i)	No
                                         Bankruptcy. Such Shareholder is not insolvent, and there has been no request for,
                                         nor has there been issued, any bankruptcy decree against such Shareholder, whether temporary
                                         or permanent, nor has any legal, administrative or other proceeding concerning the bankruptcy
                                         of such Shareholder been commenced.

 

		(j)	Each
                                         certificate, instrument, or book entry representing (i) the Medigus Shares, and (ii)
                                         any other securities issued in respect of the Medigus Shares, upon any stock split, stock
                                         dividend, recapitalization, merger, consolidation, or similar event, shall be notated
                                         with a legend. The Medigus Shares will not be registered under the Securities Act or
                                         any state securities laws and, therefore, cannot be resold unless they are registered
                                         under the Securities Act and applicable state securities laws or unless an exemption
                                         from such registration requirements is available (such as in accordance with Section
                                         144 of the Securities Act). The Shareholders are aware that Medigus is under no obligation
                                         to effect any such registration or to file for or comply with any exemption from registration.
                                         The sale and issuance of such securities have not and will not be registered under the
                                         Securities Act by reason of a specific exemption from registration which depends upon,
                                         among other things, the accuracy of the Shareholders’s representations as expressed
                                         herein.

 

		4.2	Medigus
                                         represents and warrants to the Shareholders that the following representations and warranties
                                         are true and correct in all respects as of the date hereof and shall be true and correct
                                         in all respects as of the applicable Exchange Date:

 

		(a)	Authorization;
                                         Validity. Medigus is a duly incorporated or formed and validly existing under the
                                         laws of its respective jurisdiction of incorporation. Medigus has the requisite corporate
                                         power and authority to execute and deliver this Agreement and to perform its obligations
                                         hereunder. This Agreement has been duly executed and delivered and, assuming due execution
                                         and delivery by the Shareholders, constitutes the valid and binding obligation of Medigus,
                                         enforceable in accordance with its terms and conditions except as may be limited by applicable
                                         bankruptcy, insolvency, reorganization, moratorium laws, and other laws of general application
                                         affecting the enforcement of creditors’ rights and remedies generally.

 

    5

     

    

 

		(b)	Consents.
                                         Medigus has obtained each consent, approval, permit, declaration, registration, and authorization
                                         of, and made each filing with, any person, including any applicable court, governmental
                                         or regulatory authority, commission, administrative agency, and non-governmental third
                                         party, if any, necessary to consummate the transactions contemplated hereunder.

 

		(c)	Non
                                         Contravention. Neither the execution, delivery or performance by Medigus of this
                                         Agreement or any of the transaction documents to which it is a party, nor the consummation
                                         of the transactions contemplated hereunder and thereunder, will (with or without notice
                                         or lapse of time): (a) contravene, conflict with or result in a violation of (i) any
                                         provision of the organizational documents of Medigus, (ii) any applicable law, or (iii)
                                         any provision of any contract or agreement to which Medigus is party; or (b) otherwise
                                         give any person the right to (i) declare a default or exercise any remedy under any such
                                         contract or agreement, (ii) accelerate the maturity or performance of any such contract
                                         or agreement, or (iii) cancel, terminate or modify any such contract or agreement, in
                                         each case, except as would not have and would not reasonably be expected to have or result
                                         in an adverse effect on the ability of Medigus to consummate the transactions contemplated
                                         hereunder pursuant to the terms hereof or under the transaction documents.

 

		(d)	Medigus
                                         Shares. All Medigus Shares to be issued to the Shareholders in connection with the
                                         Share Exchange will be, when issued, in accordance with the terms thereof, duly authorized,
                                         validly issued, fully paid an non-assessable. 

 

	5.	APPOINTMENT
                                         OF REPRESENTATIVE. Each Shareholder approves the
                                         designation of and designates the Representative as the representative of the Shareholder
                                         and as the attorney-in-fact and agent for and on behalf of each Shareholders for all
                                         purposes in connection with this Agreement, including with respect to the taking by the
                                         Representative of any and all actions in connection on deciding whether or not to effect
                                         the Share Exchange, and including but not limited, the exercise of the power to: (i)
                                         give and receive notices and communications to or Medigus relating to this Agreement,
                                         (ii) determine the Eventer FMV or authorize the identity and the appointment of an Appraiser,
                                         and (iii) agree to, object to, negotiate, resolve, enter into settlements and compromises
                                         in respect with this Agreement. The Shareholders shall be bound by all actions and decisions
                                         taken and consents and instructions given by the Representative in connection with this
                                         Agreement, and Medigus shall be entitled to rely on, and shall be relieved from any liability
                                         to any Shareholder for any acts done by them in accordance with, any such action, decision,
                                         consent or instruction of the Representative. After the Closing, notices or communications
                                         to or from the Representative shall constitute notice to or from each of the Shareholders.

 

	6.	MISCELLANEOUS.

 

		6.1	Expenses.
                                         Each Party shall bear its own expenses in connection with this Agreement. Without limiting
                                         the generality of the foregoing, any fees relating to the obtainment of a Valid Tax Certificate
                                         (including a ruling under Section 104H of the ITO) shall be borne by the Company.
                                         Notwithstanding the foregoing, the fees and expenses of the Appraiser shall be borne
                                         and paid for by the Company.

 

    6

     

    

 

		6.2	Confidentiality.
                                         Save as required for under applicable law, each Party hereby undertakes to the other
                                         Party to maintain the existence of this Agreement and its content in confidence, and
                                         not disclose or convey its content or existence to any person and/or entity whatsoever,
                                         other than as is reasonably required for the purpose of carrying out its obligations
                                         hereunder, without the prior written consent of the other Party.

 

		6.3	Notices.
                                         Any communications between the parties hereto or notices provided herein to be given
                                         may be given by personal delivery or mailing the same, postage prepaid, to Medigus at
                                         Omer Industrial Park, No. 7A, P.O Box 3030, Omer 8496500, Israel and to Representative
                                         at Bezalel 4, Ramat Gan, Israel; or to such other address as either party may in writing
                                         hereafter indicate. Notices shall be deemed effective on the date received.

 

		6.4	Assignment.
                                         Neither party shall assign this Agreement without the
                                         prior written consent of Medgius and the Representative. It is hereby clarified that
                                         to the extent a Shareholder transfers any of the Eventer Shares held by such Shareholder
                                         to any third party, such third Party shall not have any rights under this Agreement,
                                         including the right to exchange such Eventer Shares into Medigus Shares.

 

		6.5	Severability.
                                         The illegality or unenforceability of any provision
                                         of this Agreement shall not in any way affect or impair the legality or enforceability
                                         of the remaining provisions of this Agreement. 

 

		6.6	Governing
                                         Law.
                                         This Agreement shall be governed by and construed in
                                         accordance with the laws of the State of Israel, disregarding its conflict of laws rules.

 

		6.7	Separate
                                         Counterpart; Amendments.
                                         This Agreement may be signed in any number of counterparts,
                                         each of which shall be an original, with the same effect as if the signatures thereto
                                         and hereto were upon the same instrument. This Agreement may be amended only by an instrument
                                         in writing duly signed by all Medigus and the Representative.

 

		6.8	Entire
                                         Agreement.
                                         This agreement supersedes any previous agreement between
                                         the parties in relation to the matters dealt with herein and represents the entire understanding
                                         between the parties with respect to such matters.

 

[The
remainder of this page is intentionally left blank]

 

    7

     

    

 

IN
WITNESS WHEREOF, the parties have duly executed this Agreement effective as of the Effective Date.

 

	 	MEDIGUS
    LTD.
	 	 
	 	By: 	/s/ Eli Yoresh
	 	Name:   	Eli Yoresh
	 	Title: 	Chairman
	 	 
	 	By:	 /s/ Liron Carmel
	 	Name: 	Liron Carmel
	 	Title: 	Chief Executive Officer
	 	 
	 	EVENTER
    TECHNOLOGIES LTD.
	 	 
	 	By: 	/s/ Eli Uzan
	 	Name:	 Eli Uzan
	 	Title: 	Chairman
	 	 
	 	By: 	/s/ Julien Azoulay 
	 	Name:	 Julien Azoulay
	 	Title: 	Chief Executive Officer
	 	 
	 	/s/
    Eli Uzan
	 	ELI
    UZAN, in his capacity as a Representative

 

    8

     

    

 

IN
WITNESS WHEREOF, the parties have duly executed this Agreement effective as of the Effective Date.

 

	 	/s/ Eli Uzan
	 	ELI UZAN
	 	 
	 	/s/ Shenhav-Eventer L.P. Limited Partnership
	 	SHENHAV-EVENTER L.P. LIMITED
	 	PARTNERSHIP
	 	 
	 	/s/ Roee Grinblat
	 	ROEE GRINBLAT
	 	 
	 	/s/Joeri Kreisberg
	 	JOERI KREISBERG
	 	 
	 	/s/ Shalom Eshel
	 	SHALOM ESHEL
	 	 
	 	/s/Menachem Finkelstein
	 	MENACHEM FINKELSTEIN
	 	 
	 	/s/ Julien Azulay
	 	ALTSHULER SHACHAM, in trust for Assaf Greenfield and Pola Umnitzin, by proxy granted to Julien Azulay
	 	 
	 	/s/ Assaf Greenfeld
	 	ASSAF GREENFELD

 

 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]